Paper Details

  1. Home
  2. Paper Details

Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of HIV type 1 infection: final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903.

Author: , Angels RibasM, AsensiVíctor, BerenguerJuan, DomingoPere, GimenoJuan Luis, GonzálezJuan, MirallesPilar, PedrolEnric, Pérez-MolinaJosé Antonio, RiberaEsteban, SantamaríaJuan Miguel, SantosJesús, TerrónJosé Alberto

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Didanosine/lamivudine/efavirenz (ddI/3TC/EFV) administered with food was noninferior to lamivudine-zidovudine tablet and EFV (COM/EFV) in treating HIV-1 infection, but more patients in the COM/EFV arm discontinued therapy due to adverse events, mainly hematological toxicity.
Paper Details　
Original Abstract of the Article :
BACKGROUND: The combination of didanosine, lamivudine, and efavirenz (ddI/3TC/EFV) for the initial treatment of human immunodeficiency virus type 1 (HIV-1) infection has been insufficiently analyzed in clinical trials. METHODS: We conducted an open-label, randomized study to compare the noninferior...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1086/592114

データ提供：米国国立医学図書館（NLM）

A Battle Against HIV: Comparing Treatment Regimens

In the ongoing battle against HIV, finding the most effective and tolerable treatment options is paramount. This research compared two different drug regimens for the initial treatment of HIV-1 infection. The study aimed to determine if didanosine, lamivudine, and efavirenz (ddI/3TC/EFV) was non-inferior to the standard combination of lamivudine-zidovudine and efavirenz (COM/EFV). The researchers followed a large group of patients for 48 weeks, monitoring their viral load and other health markers.

A Tale of Two Regimens: Comparing Outcomes

The study found that both regimens were effective in reducing viral load, with no significant difference in the percentage of patients achieving an undetectable viral load after 48 weeks. However, a higher proportion of patients in the COM/EFV group discontinued treatment due to adverse events, primarily hematological toxicity.

Choosing the Right Path in the Desert of Treatment Options

Just as a camel needs a reliable guide to navigate the vast desert, patients with HIV need tailored treatment plans. This study provides valuable data for healthcare professionals when deciding on the best initial treatment regimen for patients with HIV-1 infection. Always remember to discuss your treatment options and any concerns with a healthcare professional.

Dr.Camel's Conclusion

This research provides valuable insights into the effectiveness and safety of two different drug regimens for the initial treatment of HIV-1 infection. While both regimens showed efficacy in reducing viral load, ddI/3TC/EFV appeared to have fewer adverse events. However, it’s crucial to tailor treatment plans based on individual patient characteristics and preferences. Consult with a healthcare professional to determine the best course of action for your specific situation.

Date :
  1. Date Completed 2008-10-23
  2. Date Revised 2020-12-09
Further Info :

Pubmed ID

18781872

DOI: Digital Object Identifier

10.1086/592114

Related Literature

Article Analysis
・Effects of lamivudine and zidovudine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.